- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04871438
Flash CONtinous Glucose Monitoring in TRansition to Outpatient: Libre for Type 2 Diabetes Mellitus (CONTROL-DM) (CONTROL-DM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Hospitalization often provides an opportunity to optimise the care of patients with diabetes, however, there could be destabilisation of dietary habits and diabetes therapy during admission. During transition from hospital to home, diabetes treatment may be intensified to control hyperglycemia, such as starting insulin therapy, or, de-escalated, due to risks of hypoglycaemia secondary to variable oral intake and physical activity levels peri-hospitalization.
Achieving optimal glycemic control necessitates frequent blood glucose monitoring. However, patients may perceive repeated self-monitoring of blood glucose (SMBG) as inconvenient, intrusive and laborious as it requires pricking their fingers multiple times, resulting in reduced compliance and poorer glycemic outcomes. Ambulatory flash glucose monitoring (FGM) may overcome this and facilitate more rapid achievement of euglycemia due to the benefit of immediate feedback of glucose levels with changes in diet, medication and activity.
As the transitional care period is a period of stress for patients and an opportunity to encourage behavioural change, we propose that the use of intermittent short term FGM in the first two weeks post discharge, and for another two weeks at a 6-week interval may promote behavioural change resulting in improvements in glycemic control.
Objectives:
- To explore the use of FGM in patients with T2DM with baseline HbA1c >9% and requiring insulin who at risk of hypoglycemia or hyperglycemia, in facilitating the transition care from inpatient to the ambulatory setting.
- This pilot study is exploratory to determine the logistics and feasibility of the protocol, and to collect preliminary information that will lead to a larger grant application for a larger clinical trial in the future.
Hypotheses:
- FGM use in patients with T2DM with baseline HbA1c >9% and requiring insulin would facilitate the transition of care from inpatient to the ambulatory setting, resulting in improved glycemic control, as measured by HbA1c at 12 weeks.
- FGM use in the transitional care period would lead to improved time in range (TIR), reduced time in hypoglycaemia and hyperglycaemia, reduced readmission rates for hypo or hyperglycaemia, improved quality of life, reduced loss to follow-up and encourage individual lifestyle modification, without a significant increase in costs and manpower utilization.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline WS Hoong
- Phone Number: +65 63573737
- Email: caroline_hoong@whc.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- Tan Tock Seng Hospital
-
Contact:
- Caroline WS Hoong
- Phone Number: +65 63573735
-
Principal Investigator:
- Daniel EK Chew
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 21-80 inclusive
- HbA1c>9% on insulin
- Requiring inpatient adjustment of DM medication if meets any of the following:
- A) Hypoglycemia (defined as glucose < 4 mmol/l occurring 2 or more times at least 3 hours apart in the last 72 hours or any glucose <2.5 mmol/l in the last 24 hours)
- B) Hyperglycemia (defined as glucose > 14 mmol/l occurring 2 or more times in the last 36 hours, or any glucose > 24 mmol/l in the last 24 hours)
- Desire to lower HbA1c to a target of 7%
- Willing to wear FGM device
- Willing and able to use FreeStyle Librelink app on personal device
- Willing to avoid use of ascorbic acid throughout the study
- Willing to perform SMBG (by history) of an average of at least 4 times a day, 3 days a week
Exclusion Criteria:
- T1DM
- Pregnant or planning pregnancy during duration of study
- Unable to use or unwilling to comply with study requirements
- Use of personal FGM within 3 months of screening or plan to use personal FGM during the course of the study
- On ascorbic acid
- Extensive skin changes that preclude wearing the sensor on normal skin (e.g. extensive psoriasis, extensive eczema, recent burns or severe sunburn, extensive tattoos, dermatitis herpetiformis)
- Known allergy to medical-grade adhesives
- Renal insufficiency (eGFR<30)
- Pancreatic insufficiency or history of pancreatitis
- Patients on any structured weight reduction interventions such as prescription weight loss medications, bariatric surgery, or protein sparing modified fast during the course of the study.
- Current or anticipated short term uses of glucocorticoids (oral, injectable, or intravenous. Long-term stable glucocorticoid doses are allowed, such as for treatment of rheumatoid arthritis or Addison's disease.
- Any medical condition that would make it inappropriate to target an HbA1c of <7%
- Currently abusing illicit drugs, alcohol or prescription drugs
- Any condition per investigator assessment, that could impact reliability of the HbA1c measurement, such as but not limited to hemoglobinopathy, haemolytic anaemia, chronic liver disease, chronic GI blood loss, recent red blood cell transfusion or erythropoietin administration within 3 months prior to screening
- Current participation in another investigational study (must have completed any prior studies at least 30 days prior to being enrolled in this study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FGM
Flash glucose monitoring at weeks 0-2, weeks 6-8 post-discharge
|
Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks.
Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
Other Names:
|
No Intervention: SMBG
Self-monitoring of blood glucose at least 4 times a day, 3 days a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: 6 weeks, 12 weeks
|
Assess change in glycaemic control between groups
|
6 weeks, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
% Time in range, % Time below range, % Time above range
Time Frame: 12 weeks
|
Glucose in-range defined as 3.9-10.0mmol/l,
below range = glucose <3.9mmol/l, above range = glucose >10.0mmol/l
|
12 weeks
|
Glycaemic variability
Time Frame: 12 weeks
|
Defined by SD and CV
|
12 weeks
|
Severe hypoglycemia events
Time Frame: 12 weeks
|
Defined by number of hypoglycemic events requiring 3rd party to rescue
|
12 weeks
|
Resource utilization
Time Frame: 12 weeks
|
Defined as time used for telehealth and clinic consults
|
12 weeks
|
Number of re-admissions for dysglycemia or device-related complications
Time Frame: 12 weeks
|
Within duration of study
|
12 weeks
|
Diabetes Distress Scale (DDS)
Time Frame: 12 weeks
|
This 17-item scale lists potential problem areas that people with diabetes may experience, and can denote the degree to which they are or are not affected.
Min-Max score of 1-6, where higher score indicates more distress.
|
12 weeks
|
Audit of Diabetes-Dependent Quality-of-Life Questionnaire (ADDQoL)
Time Frame: 12 weeks
|
This questionnaire assesses the impact of diabetes on 19 life domains including physical functioning, symptoms, psychological well-being, social well-being, role activities and personal constructs, and allows them to indicate the importance of these domains to their quality of life.
Average weighted impact score Min to Max -9 to +3, where a lower score indicates poorer quality of life.
|
12 weeks
|
Glucose Monitoring Satisfaction Score (GMSS)
Time Frame: 12 weeks
|
This 15-item scale evaluates patient satisfaction with their glucose monitoring device and its impact on their quality of life including 4 sub-sections on openness, emotional burden, behavioural burden and worthwhileness.
Min-max score of 1-5, where a higher score indicates greater satisfaction.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean glucose
Time Frame: 12 weeks
|
Mean glucose
|
12 weeks
|
Dietary intake
Time Frame: 12 weeks
|
measured in kcal/day
|
12 weeks
|
Exercise duration
Time Frame: 12 weeks
|
measured in minutes/week
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Caroline WS Hoong, Woodlands Health Campus
Publications and helpful links
General Publications
- Levitt DL, Silver KD, Spanakis EK. Inpatient Continuous Glucose Monitoring and Glycemic Outcomes. J Diabetes Sci Technol. 2017 Sep;11(5):1028-1035. doi: 10.1177/1932296817698499. Epub 2017 Mar 14.
- Hirschman KB, Bixby MB. Transitions in Care from the Hospital to Home for Patients With Diabetes. Diabetes Spectr. 2014 Aug;27(3):192-5. doi: 10.2337/diaspect.27.3.192.
- Rushakoff RJ, Sullivan MM, MacMaster HW, Shah AD, Rajkomar A, Glidden DV, Kohn MA. Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study. Ann Intern Med. 2017 May 2;166(9):621-627. doi: 10.7326/M16-1413. Epub 2017 Mar 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSRB 2020/01468
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Treated With Insulin
-
Institute for Clinical and Experimental MedicineRecruitingType 2 Diabetes Treated With InsulinCzechia
-
Abbott Diabetes CareNot yet recruitingType 2 Diabetes Treated With InsulinFinland
-
Steno Diabetes Center CopenhagenCompletedType 2 Diabetes Treated With InsulinDenmark
-
Hospital Universitario San IgnacioCompletedType 2 Diabetes Treated With InsulinColombia
-
DiabeloopAGIR à Dom; Icadom; CHU Grenoble AlpesCompletedType 2 Diabetes Treated With InsulinFrance
-
Klavs Würgler HansenSteno Diabetes Center Aarhus, DenmarkRecruitingType 2 Diabetes Treated With InsulinDenmark
-
Boston Medical CenterNovo Nordisk A/SCompletedType 2 Diabetes Treated With InsulinUnited States
-
Centre hospitalier de l'Université de Montréal...CHU de Quebec-Universite Laval; Institut de Recherches Cliniques de MontrealWithdrawnType 2 Diabetes Treated With InsulinCanada
-
Ege UniversityThe Scientific and Technological Research Council of TurkeyCompletedType 2 Diabetes Treated With InsulinTurkey
-
Abbott Diabetes CareNot yet recruitingType 2 Diabetes Treated With InsulinItaly
Clinical Trials on Flash glucose monitoring
-
Campus Bio-Medico UniversityRecruiting
-
Jena University HospitalRecruitingGestational Diabetes | Gestational Diabetes Mellitus in PregnancyGermany
-
University of Lausanne HospitalsUniversity Hospital, GenevaCompleted
-
Charles University, Czech RepublicUnknownDiabetes Mellitus, Type 1Czechia
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaCompletedDiabetes Mellitus, Type 1Italy
-
RenJi HospitalUnknownCritical Illness | Systemic Lupus Erythematosus | Diabetic Blood Glucose MonitoringChina
-
Singapore General HospitalNational University Hospital, Singapore; National University Polyclinics, Singapore and other collaboratorsActive, not recruitingDiabetes Mellitus, Type 2 | Flash Glucose MonitoringSingapore
-
University of CataniaCompleted
-
Rio de Janeiro State UniversityRecruiting